Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 745,740 | 712,029 | 648,833 | 646,207 | 581,329 |
| Cost of Goods | 188,457 | 130,459 | 125,180 | 120,722 | 128,041 |
| Gross Profit | 557,283 | 581,570 | 523,653 | 525,485 | 453,288 |
| Operating Expenses | 443,847 | 461,577 | 435,371 | 526,605 | 422,804 |
| Operating Income | 113,893 | 120,452 | 88,462 | -398 | 30,525 |
| Interest Expense | 2,968 | 3,574 | 3,547 | 6,098 | 3,779 |
| Other Income | 23,516 | 15,258 | 20,632 | 25,823 | 14,923 |
| Pre-tax Income | 134,441 | 132,136 | 105,547 | 19,327 | 41,669 |
| Income Tax | 28,361 | 24,962 | 16,885 | -1,048 | 1,291 |
| Net Income Continuous | 106,080 | 107,174 | 88,662 | 20,375 | 40,378 |
| Net Income | $106,080 | $107,174 | $88,662 | $20,375 | $40,378 |
| EPS Basic Total Ops | 0.56 | 0.56 | 0.47 | 0.11 | 0.21 |
| EPS Basic Continuous Ops | 0.56 | 0.56 | 0.47 | 0.11 | 0.21 |
| EPS Diluted Total Ops | 0.55 | 0.55 | 0.46 | 0.10 | 0.21 |
| EPS Diluted Continuous Ops | 0.54 | 0.53 | 0.45 | 0.11 | 0.21 |
| EPS Diluted Before Non-Recurring Items | 0.74 | 0.77 | 0.49 | 0.26 | 0.26 |
| EBITDA(a) | $130,958 | $144,739 | $113,310 | $24,016 | $53,962 |